Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Industry: Electromedical & Electrotherapeutic Apparatus Peers: Abbott Laboratories MICRON SOLUTIONS INC /DE/ Avinger Inc Dynatronics Corp INVO Fertility Inc Intelligent Bio Solutions Inc OMNIA WELLNESS INC. Solana Co MINERVA SURGICAL INC ENvue Medical Inc